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OBJECTIVES: To evaluate the perceived state of health (PSH)of
renal transplant N = 359). METHODS: The differences in PSH
according to sex are presented here for patients included to date
at all centres in the study. The analysis corresponds to the base
moment, when they are on the transplant waiting list. A generic
PSH proﬁle, the SF-36 Health Questionnaire and an index, EQ-
5D are applied to each patient. To evaluate the differences with
respect to sex in both measurements, the Student-t test was used
for independent samples and the chi-squared test for contingency
tables. RESULTS: For the whole sample, the PCS score was
42.09 8.6, MCS 46.6 11.5 and VAS 60.1 17.4. Females had
worse PSH than males on 7 of 8 dimensions of SF-36 (the excep-
tion being Social Functioning) and in the two summary scores:
PCS (40.2 9.1 in females, 43.3 8 in males) and MCS (44.9 11.7
vs. 47.7 11.2) (p < 0.05). With regard to EQ-5D, females showed
a similar score to males in VAS (58.2 18.1 vs. 61.4 16.9), but
poorer scores in 4 of the 5 dimensions (except in personal care):
mobility (p = 0.047), everyday tasks (p = 0.0001) and anxiety-
depression (p = 0.006). The PSH of patients of both sexes on
renal transplant waiting lists at the centres studied is worse than
that to be expected in the general population as regards physi-
cal health (score under 45 points), but similar as regards mental
health (score over 45 points). VAS does not appear to be a good
measurement of PSH as it oversimpliﬁes, including as it does
physical and mental aspects in a single index. CONCLUSIONS:
Among these patients, the PSH of females is clearly worse than
that of males, as is also the case in the general population,
demonstrating the need for standardisation with respect to sex
of scores on PSH questionnaires.
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OBJECTIVES: Compare the PRO endpoints used in the
approval of medicinal products for urinary incontinence, which
led to a PRO labeling claim, with those recommended by the
EMEA note for guidance on the clinical investigation of medic-
inal products for the treatment of urinary incontinence
(CPMP/EWP/18/01 ﬁnal). METHODS: The PROLabels data-
base is a unique on-line tool which collects information on the
medicinal products for which the FDA and/or the EMEA have
granted a PRO labeling claim. Using this database we searched
the products with a urinary incontinence indication, and
approved by the European Commission through the centralized
procedure. For each drug, we analyzed the endpoints used in the
clinical studies to assess treatment efﬁcacy. These endpoints were
then compared to those recommended by the CPMP guidance
for the treatment of urinary incontinence. RESULTS: Three
products have been retrieved, for which a marketing authoriza-
tion in Europe to treat urinary incontinence was granted; all of
which have been approved between June and October 2004. For
the three products, the clinical outcomes measures used for eval-
uation included subjective outcome measures and quantiﬁcation
of symptoms (i.e. diaries and quality of life instruments), in
accordance with the CPMP guidance. Only pad weighing tests
were not used in these studies. In all 3 cases, quantiﬁcation of
symptoms resulted in a PRO claim. Quality of life assessment
generated a labeling claim for two products, and subjective out-
comes (global improvement) for one. CONCLUSIONS: In the
evaluation of medicinal products for urinary incontinence, there
is a close adherence to the guidance concerning the choice of
study endpoints, with different rates of success concerning the
PRO claims obtained. The PROLabels database has proven its
usefulness in retrieving the PRO endpoints used in clinical studies
for products approval in a speciﬁc indication and in comparison
to the guidance.
PUK23
IMPACT OF OVERACTIVE BLADDER ON FREQUENCY OF
SEXUAL ACTIVITY AND SEXUAL SATISFACTION IN WOMEN:
RESULTS FROM THE EPIC STUDY
Irwin DE1, Milsom I2, Reilly K3, Hunskaar S4, Kopp Z3, Herschorn S5,
Coyne KS6, Kelleher C7,Artibani W8, Hampel C9,Abrams P10
1University of North Carolina, North Carolina, NC, USA, 2Sahlgrenska
Academy at Goteborg University, Göteborg, Sweden, 3Pﬁzer, Inc, New
York, NY, USA, 4University of Bergen, Bergen, Norway, 5University of
Toronto,Toronto, ON, Canada, 6United BioSource Corporation,
Bethesda, MD, USA, 7St.Thomas’ Hospital, London, UK, 8University of
Padova, Padova, Italy, 9Johannes-Gutenberg-Universität, Mainz, Germany,
10Southmead Hospital, Bristol Urological Institute, Bristol, UK
OBJECTIVES: To evaluate the impact of overactive bladder
(OAB) on the frequency of sexual activity and sexual enjoyment
in women. METHODS: A population-based telephone survey
was conducted in Sweden, Italy, Germany, the UK, and Canada
to evaluate the prevalence and burden of OAB symptoms using
current International Continence Society deﬁnitions. A nested
case-control analysis was performed on data collected from
women with OAB (cases, n = 995) and without OAB (controls,
n = 1524). Survey respondents reported whether they experi-
enced a decrease in sexual activity or enjoyment of sex owing to
urinary symptoms and whether they had physician-diagnosed
depression. Factors inﬂuencing sexual activity and sexual satis-
faction were analyzed using logistic regression. RESULTS:
Among participants aged ≤50 and >50 years the following
reported being sexually active during the past 12 months, respec-
tively: 78% and 41% of controls, 74% and 36% of cases
without incontinence, and 74% and 35% of cases with inconti-
nence. Cases were signiﬁcantly more likely to report decreased
sexual activity caused by urinary symptoms than were controls
among respondents aged ≤50 (odds ratio [OR] = 4.3, 95% con-
ﬁdence interval [CI] = 2.4–7.7) and those aged >50 years (OR =
2.6, 95% CI = 1.2–5.2), after controlling for incontinence and
depression. Among sexually active participants (n = 1420), OAB
cases were signiﬁcantly more likely to report decreased sexual
enjoyment due to urinary symptoms than were controls (≤50 y:
OR = 5.8, 95% CI = 3.0–11.4; >50 y: OR = 3.1, 95% CI =
1.1–8.9). CONCLUSIONS: This is the ﬁrst multinational, 
population-based study to assess the impact of OAB on sexual
activity and enjoyment in women. Women with OAB were 
signiﬁcantly more likely than were controls to report decreased
sexual activity and enjoyment due to urinary symptoms, even
after adjusting for incontinence and depression. The impact of
OAB on sexual activity and enjoyment appeared greatest in
younger women (≤50 years of age).
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